Parkins C S, Bush C, Price P, Steel G G
Radiotherapy Research Unit, Institute of Cancer Research, Sutton, Surrey, UK.
Cell Prolif. 1991 Mar;24(2):171-9. doi: 10.1111/j.1365-2184.1991.tb01147.x.
Cell proliferation was investigated in human tumour xenografts using bromodeoxyuridine (BrdUrd) labelling, evaluated either by flow cytometry or in tissue sections, and also using the proliferation marker Ki-67. BrdUrd labelling was found to increase when cryostat tumour sections were digested with an enzymic solution. This yielded a labelling index up to four times higher than that obtained using the flow cytometer. Ki-67 indices were found to be higher than those reported for human tumour biopsies, as may be expected due to the enhanced growth rate of the xenografts. Significant heterogeneity was observed in the results for cervix, breast and bladder tumours, and the results of the three methods were poorly correlated. However, three of the four tumour types showed that the tumour with the lowest Ki-67 index also had the longest potential doubling time. Since the measurement of Ki-67 index was found technically easier to perform, and also adequately reflects relative tumour cell proliferation, it is preferred over the other techniques.
利用溴脱氧尿苷（BrdUrd）标记法对人肿瘤异种移植物中的细胞增殖进行了研究，通过流式细胞术或在组织切片中进行评估，同时还使用了增殖标志物Ki-67。发现当用酶溶液消化冷冻切片机制作的肿瘤切片时，BrdUrd标记会增加。这产生的标记指数比使用流式细胞仪获得的标记指数高出四倍。正如异种移植物生长速率增强所预期的那样，发现Ki-67指数高于人类肿瘤活检报告的指数。在子宫颈、乳腺和膀胱肿瘤的结果中观察到显著的异质性，并且三种方法的结果相关性很差。然而，四种肿瘤类型中的三种显示，Ki-67指数最低的肿瘤也具有最长的潜在倍增时间。由于发现Ki-67指数的测量在技术上更容易进行，并且也能充分反映相对肿瘤细胞增殖，因此它比其他技术更受青睐。
